| "Bacillus ramosus" Veillon and Zuber 1898| "Erysipelatoclostridium ramosum" Yutin and Galperin 2013| "Nocardia ramosa" Vuillemin 1931| "Ramibacterium ramosum" (Veillon and Zuber 1898) Prevot 1938| ATCC 25582| Bacillus ramosus| BCRC 14518| CCRC 14518| CCRC:14518| CCUG 24038| Clostridium ramosum| Clostridium ramosum (Veillon and Zuber 1898) Holdeman et al. 1971| DSM 1402| Erysipelatoclostridium ramosum| JCM 1298| NCIMB 10673| NCTC 11812| Nocardia ramosa| Ramibacterium ramosum| VPI 0427
Gut microbiota: Thomasclavelia ramosa is a member of the human gut microbiota, meaning it resides within the gastrointestinal tract. The gut microbiota plays a vital role in human health, influencing various physiological processes such as digestion, metabolism, immune function, and protection against pathogens.
Metabolic capabilities: While specific metabolic capabilities of Thomasclavelia ramosa are not well-characterized, bacteria within the family Lachnospiraceae are known for their ability to ferment complex carbohydrates, producing short-chain fatty acids (SCFAs) and other metabolites. SCFAs, such as acetate, propionate, and butyrate, serve as important energy sources for colonocytes and have been associated with various health benefits, including maintenance of gut barrier function, modulation of immune responses, and regulation of inflammation.
Associations with health conditions: Alterations in the composition and function of the gut microbiota, including changes in the abundance of specific bacterial species like Thomasclavelia ramosa, have been implicated in various health conditions, including inflammatory bowel diseases (IBD), obesity, metabolic syndrome, and colorectal cancer. However, the specific role of Thomasclavelia ramosa in the development or progression of these conditions is not yet understood.
Probiotic potential: Given its presence in the gut microbiota, Thomasclavelia ramosa may have potential applications as a probiotic or in microbial-based therapies aimed at modulating gut microbiota composition and function. However, further research is needed to assess its safety, efficacy, and potential benefits in human health.
Research gaps: Thomasclavelia ramosa is a newly identified bacterium, and research on its metabolic capabilities, ecological role, and potential health impacts is ongoing. More studies are needed to elucidate its interactions with the host, its metabolic activities, and its contributions to gut health and disease.
Other Sources for more information:
R2 | Slope | Tax Name | Parent Chart |
---|---|---|---|
0.5046504139900208 | -0.7562157511711121 | Bradyrhizobium sp. BTAi1 | Parent Taxa |
0.3484395742416382 | 0.572002112865448 | Blautia argi | Parent Taxa |
0.32818636298179626 | 0.5801454186439514 | Mediterraneibacter gnavus | Parent Taxa |
0.3026401698589325 | 0.5541279911994934 | [Clostridium] innocuum | Parent Taxa |
0.2975628972053528 | 0.5250658988952637 | Bifidobacterium eulemuris | Parent Taxa |
0.27441924810409546 | 0.5270520448684692 | Enterocloster bolteae | Parent Taxa |
0.2510116994380951 | 0.4933728575706482 | Enterocloster clostridioformis | Parent Taxa |
R2 | Slope | Tax Name | Parent Chart |
---|---|---|---|
0.350793719291687 | 0.615709125995636 | Blautia argi | Parent Taxa |
0.31042566895484924 | 0.5510187745094299 | Mediterraneibacter gnavus | Parent Taxa |
0.29440775513648987 | 0.5407033562660217 | [Clostridium] innocuum | Parent Taxa |
0.26880455017089844 | 0.5174545645713806 | Enterocloster bolteae | Parent Taxa |
0.25778162479400635 | 0.5491245985031128 | Anaerostipes caccae | Parent Taxa |
0.25159376859664917 | 0.5127250552177429 | Enterocloster clostridioformis | Parent Taxa |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]